Genomic Markers Could Predict Radiation Sensitivity
The effectiveness of radiotherapy varies greatly between tumors. Finding gene signatures to predict the radiation response could better guide the clinicians to personalize treatment plans. Professor Venkata Manem, afﬁliated with the Faculty of Medicine at Université Laval and the Centre de recherche CHU de Québec - Université Laval, has made a promising step to advance pre-clinical research in the ﬁeld of precision radiation oncology. The study was published in the scientiﬁc journal BMC Cancer.
Currently, doctors use a “one-size-ﬁts-all” paradigm for radiotherapy, with a given dose and frequency of treatment, regardless of the tumor’s genomic features.
“Some cancers will be more sensitive or more resistant to different types of radiation regimen. By identifying patients who can beneﬁt from lower doses, we could reduce the treatment’s toxicity. While at the same time, we could adjust the dose for more resistant tumors, or combine it with other therapies,” explains Manem, formerly an assistant professor at the Université du Québec à Trois-Rivières.
For now, the developed radiosensitivity markers can be applied across all cancers in general, but the team is hoping to build biomarkers that are tissue speciﬁc. “With the availability of tissue-speciﬁc data, we could eventually have signatures for different types of cancers such as breast, prostate and lung cancers,” enthuses Professor Venkata Manem.
“All tumors are different, even if they are classiﬁed in the same group, at the same stage, and with the same anatomical features. They differ in multiple aspects, such as mutations present, microenvironment, and immune component. All these factors can affect the radiation response,” adds Alona Kolnohuz, ﬁrst author of the study.
Using cell line data coupled with bioinformatics and machine learning-based approaches, the research team has built a molecular predictor of radiation response that could be tested in a pre-clinical setting, before being implemented in clinical studies.
“Most studies in the ﬁeld use the number of cells that survive at a given radiation dose, say at 2Gy of radiation dose, which is equivalent to looking at a single point to conclude. Our approach uses the area under the radiation dose-response curve (AUC) instead. Based on our ﬁndings, we concluded that AUC should be considered as a pre-clinical radioresponse indicator in future studies as it captures a wider range of biological processes,” explains Professor Manem.
The next stage of his research involves validating the developed molecular signature in patient data and building a clinical assay using interpretable machine learning based methods along with identifying radiosensitizing compounds that can increase the therapeutic efﬁcacy of radiation.
“With the emerging OMICS and AI-driven technologies, time is now ripe for precision medicine to take a big leap away from the conventional ‘one-size-ﬁts-all’ framework,” says Venkata Manem. We envision that the developed gene signature of radiation sensitivity has the enormous potential to aid decision-making, personalize treatments, and improve outcomes.
Call for Papers
ARO is seeking original case reports, research articles, and review articles on innovative topics offering practical applications in radiation oncology. Manuscripts undergo a double-blinded external peer review process, and there is no submission fee.
- First Clinical Results Published for 177Lu-rhPSMA-10.1 in mCRPC Trial
- Opaganib Shown to Protect Against Radiation-Induced Lung Inflammation
- Fusion Licenses Actinium-Based PSMA Targeted Radiotherapy From Heidelberg University and Euratom
- Future of Theranostics in Neurooncology Looks Promising With Recent Advancements
- First Cellular Therapy for Unresectable or Metastatic Melanoma Receives FDA Approval